Foralumab
Foralumab is an immunomodulator. It binds to CD3 epsilon.[1]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD3 epsilon |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
|
TZLS-501 is a class of monoclonal antibody mAb an anti-interleukin-6 receptor and in accordance with recent testing carried out, has revealed that it has significance in a role to treat coronavirus patients with severe lung damage.[2]
Doctors in China carrying out clinical studies suggest anti-IL-6R MABs could treat COVID-19 patients with elevated IL-6 levels of lung damage. The Canadian company TIZIANA's anti-IL-6R MAB binds the membrane bound and soluble forms of IL-6R. Thus IL-6 levels are reduced in the blood. IL-6 in excessive quantities is thought to drive chronic inflammation and is associated with severe lung damage caused by COVID-19 infection.[3]
References
- World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
- https://www.proactiveinvestors.co.uk/companies/news/914735/tiziana-life-sciences-has-potential-drug-to-treat-coronavirus-patients-with-severe-lung-damage-914735.html
- Bioworld.com|https://www.bioworld.com/articles/433708-covid-19-drug-development-continues-to-surge
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.